These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Characterizing Frailty In Myeloproliferative Neoplasms: results from the ORCHID study. Chornenki NLJ; Siegal DM; Qamar K; Woolgar S; Rangarajan S; Karampatos S; Leong DP; Hillis CM Leuk Res; 2022 Feb; 113():106788. PubMed ID: 35042128 [No Abstract] [Full Text] [Related]
23. Cause-specific mortality following polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the US population, 2001-2017. Dores GM; Curtis RE; Linet MS; Morton LM Am J Hematol; 2021 Dec; 96(12):E451-E454. PubMed ID: 34559904 [No Abstract] [Full Text] [Related]
24. Incidence of myeloproliferative neoplasms in Calgary, Alberta, Canada. Heppner J; Nguyen LT; Guo M; Naugler C; Rashid-Kolvear F BMC Res Notes; 2019 May; 12(1):286. PubMed ID: 31126326 [TBL] [Abstract][Full Text] [Related]
25. Myeloproliferative disorders in dogs and cats. Harvey JW Vet Clin North Am Small Anim Pract; 1981 May; 11(2):349-81. PubMed ID: 7032050 [No Abstract] [Full Text] [Related]
26. Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union. Moulard O; Mehta J; Fryzek J; Olivares R; Iqbal U; Mesa RA Eur J Haematol; 2014 Apr; 92(4):289-97. PubMed ID: 24372927 [TBL] [Abstract][Full Text] [Related]
27. Myeloproliferative neoplasms and JAK2 mutations. Almedal H; Vorland M; Aarsand AK; Grønningsæter IS; Bruserud Ø; Reikvam H Tidsskr Nor Laegeforen; 2016 Dec; 136(22):1889-1894. PubMed ID: 27929554 [TBL] [Abstract][Full Text] [Related]
28. Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients. Mora B; Rumi E; Guglielmelli P; Barraco D; Maffioli M; Rambaldi A; Caramella M; Komrokji R; Gotlib J; Kiladjian JJ; Cervantes F; Devos T; Palandri F; De Stefano V; Ruggeri M; Silver RT; Benevolo G; Albano F; Cavalloni C; Pietra D; Barbui T; Rotunno G; Cazzola M; Vannucchi AM; Giorgino T; Passamonti F Cancer Med; 2019 Aug; 8(9):4089-4092. PubMed ID: 31173472 [TBL] [Abstract][Full Text] [Related]
29. A clinical update in polycythemia vera and essential thrombocythemia. Tefferi A; Solberg LA; Silverstein MN Am J Med; 2000 Aug; 109(2):141-9. PubMed ID: 10967156 [TBL] [Abstract][Full Text] [Related]
30. Analysis of clinical characteristics of bone marrow proliferative tumor progression to acute myeloid leukemia. Li Y; Zhang XY; Han J; Wang L Cancer Biomark; 2018; 23(4):469-472. PubMed ID: 30452397 [TBL] [Abstract][Full Text] [Related]
32. JAK2-v617F mutation is associated with clinical and laboratory features of myeloproliferative neoplasms. Duletić AN; Dekanić A; Hadzisejdić I; Kusen I; Matusan-Ilijas K; Grohovac D; Grahovac B; Jonjić N Coll Antropol; 2012 Sep; 36(3):859-65. PubMed ID: 23213945 [TBL] [Abstract][Full Text] [Related]
33. Incidence of chronic myeloproliferative disorders in the city of Göteborg, Sweden 1983-1992. Ridell B; Carneskog J; Wedel H; Vilén L; Høgh Dufva I; Mellqvist UH; Brywe N; Wadenvik H; Kutti J Eur J Haematol; 2000 Oct; 65(4):267-71. PubMed ID: 11073167 [TBL] [Abstract][Full Text] [Related]
34. Incidence, Survival and Prevalence Statistics of Classical Myeloproliferative Neoplasm in Korea. Lim Y; Lee JO; Bang SM J Korean Med Sci; 2016 Oct; 31(10):1579-85. PubMed ID: 27550486 [TBL] [Abstract][Full Text] [Related]
35. Real-world status of treatment for lymphoid neoplasms developed during the course of myeloproliferative neoplasms in Japan. Edahiro Y; Ochiai T; Hashimoto Y; Ichii M; Okatani T; Omura H; Nakajima K; Sasaki M; Ando J; Takaku T; Koike M; Izumiyama K; Hiraga J; Yano T; Usuki K; Ohtsuka E; Yokoyama K; Oyake T; Takahashi N; Nishida T; Nakao T; Fukuda Y; Akasaka T; Mugitani A; Ando M; Komatsu N Hematology; 2024 Dec; 29(1):2340149. PubMed ID: 38626148 [TBL] [Abstract][Full Text] [Related]
36. The relationship of erythromonocytic leukemia to other myeloproliferative disorders. Shaw MT; Bottomley SS; Bottomley RH; Hussein KK Am J Med; 1973 Oct; 55(3):542-8. PubMed ID: 4355172 [No Abstract] [Full Text] [Related]
37. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation]. Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211 [TBL] [Abstract][Full Text] [Related]
38. Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors. Cerquozzi S; Tefferi A Blood Cancer J; 2015 Nov; 5(11):e366. PubMed ID: 26565403 [TBL] [Abstract][Full Text] [Related]
40. Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia. Johansson P Semin Thromb Hemost; 2006 Apr; 32(3):171-3. PubMed ID: 16673273 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]